Journal of Shanghai Jiao Tong University (Medical Science) >
6-OHDA-induced Parkinson disease mice exhibit senescent phenotypes characterized by upregulation of p16Ink4a and astrocyte senescence
Online published: 2021-08-03
Supported by
Funding Information National Natural Science Foundation of China(91849121)
·To explore whether 6-hydroxydopamine(6-OHDA)-induced Parkinson disease (PD) mouse models have senescent phenotypes and explore the changes of senescence-related glial cells.
·Thirty 9?10 months old C57BL/6J male mice were divided into Sham-operated group (n=15) and 6-OHDA group (n=15). PD mouse models were established by stereotactic injection of 6-OHDA into striatum. The neurological function deficit was evaluated by rotarod test and apomorphine (APO)-induced rotational behavior on the 21st day after modeling. The brain was taken after the last behavioral experiment. Western blotting was used to detect the protein content of tyrosine hydroxylase (TH) in both caudate putamen (CPu) and substantia nigra (SN) regions. Immunofluorescence was used to observe the expression of glial cells and aging marker p16Ink4a / p21 in both CPu and SN regions. RT-qPCR was also used to detect the expression and changes of cyclin-dependent kinase inhibitor including p16Ink4a, p15Ink4b, p19Ink4d, p21 and p27Kip1, and senescence-associated secretory phenotype including Cxcl10, Ccl2, tumor necrosis factor-α (Tnf-α), interleukin-1α (Il-1α), Il-1β, Il-6 and matrix metalloproteinase 3 (MMP3).
·The decreased falling latency in rotarod test (P=0.000), the increased number of rotations induced by APO (P=0.000) and the loss of TH protein measured by Western blotting (P=0.000), suggested that 6-OHDA unilateral striatum mouse model of PD was successfully established. Immunofluorescence staining showed that the upregulation of an aging marker p16Ink4a in both CPu and SN regions of the 6-OHDA group compared with the Sham group, but p21 was not significantly expressed in both groups; senescent astrocytes, microglia and oligodendrocytes were accumulated in CPu and SN regions as well, while the number of astrocytes was larger than the other two types of glia cells (P<0.05). RT-qPCR results showed that, compared with those of the Sham group, p15Ink4b, p16Ink4a and p19Ink4d in CPu and SN regions of the 6-OHDA group were up-regulated (P<0.05); p21 was slightly up-regulated, but the difference was not statistically significant (P?0.05); p27kip1 was slightly up-regulated, but statistically significant difference only presented in SN region (P=0.016). RT-qPCR also showed that, compared with those of the Sham group, the levels of Cxcl10, Ccl2, Il-1α and Il-6 were significantly up-regulated while Il-1β was significantly decreased in CPu region of the 6-OHDA group (P<0.05); the levels of Ccl2, Tnf-α, Il-1α and Il-6 were significantly increased while Mmp3 and Il-1β were significantly decreased in SN region of the 6-OHDA group (P<0.05).
·6-OHDA-induced PD mice exhibit senescent phenotypes characterized by upregulation of p16Ink4a and astrocyte senescence.
Xiao YUAN , Ye-ye TIAN , Zheng XUE . 6-OHDA-induced Parkinson disease mice exhibit senescent phenotypes characterized by upregulation of p16Ink4a and astrocyte senescence[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2021 , 41(7) : 876 -883 . DOI: 10.3969/j.issn.1674-8115.2021.07.005
1 | van Bulck M, Sierra-Magro A, Alarcon-Gil J, et al. Novel Approaches for the treatment of Alzheimer′s and Parkinson′s disease[J].Int J Mol Sci, 2019, 20(3): 719. |
2 | Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson′s disease: dopaminergic pathophysiology and treatment[J]. Lancet Neurol, 2009, 8(5): 464-474. |
3 | Saez-Atienzar S, Masliah E. Cellular senescence and Alzheimer disease: the egg and the chicken scenario[J]. Nat Rev Neurosci, 2020, 21(8): 433-444. |
4 | Zhang P, Kishimoto Y, Grammatikakis I, et al. Senolytic therapy alleviates Aβ-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer′s disease model[J].Nat Neurosci, 2019, 22(5):719-728. |
5 | Riessland M, Kolisnyk B, Kim TW, et al. Loss of SATB1 induces p21-dependent cellular senescence in post-mitotic dopaminergic neurons[J]. Cell Stem Cell, 2019, 25(4): 514-530.e8. |
6 | Kirkland JL, Tchkonia T. Senolytic drugs: from discovery to translation[J]. J Intern Med, 2020, 288(5): 518-536. |
7 | Tieu K. A guide to neurotoxic animal models of Parkinson′s disease[J]. Cold Spring Harb Perspect Med, 2011, 1(1): a009316. |
8 | Gubellini P, Kachidian P. Animal models of Parkinson′s disease: an updated overview[J]. Rev Neurol (Paris), 2015, 171(11): 750-761. |
9 | Hernandez-Segura A, Nehme J, Demaria M. Hallmarks of cellular senescence[J]. Trends Cell Biol, 2018, 28(6): 436-453. |
10 | Lozano-Torres B, Estepa-Fernández A, Rovira M, et al. The chemistry of senescence[J].Nat Rev Chem, 2019, 3(7): 426-441. |
11 | Sacco A, Belloni L, Latella L. From development to aging: the path to cellular senescence[J]. Antioxid Redox Signal, 2021, 34(4): 294-307. |
12 | von Kobbe C. Targeting senescent cells: approaches, opportunities, challenges[J]. Aging, 2019, 11(24): 12844-12861. |
13 | Coppé JP, Desprez PY, Krtolica A, et al. The senescence-associated secretory phenotype: the dark side of tumor suppression[J]. Annu Rev Pathol, 2010, 5: 99-118. |
14 | Schaum N, Lehallier B, Hahn O, et al. Ageing hallmarks exhibit organ-specific temporal signatures[J]. Nature, 2020, 583(7817): 596-602. |
15 | Gordon R, Albornoz EA, Christie DC, et al. Inflammasome inhibition prevents alpha-synuclein pathology and dopaminergic neurodegeneration in mice[J].Sci Transl Med, 2018, 10(465): eaah4066. |
16 | Mangan MSJ, Olhava EJ, Roush WR, et al. Targeting the NLRP3 inflammasome in inflammatory diseases[J]. Nat Rev Drug Discov, 2018, 17(8): 588-606. |
17 | Heneka MT. Microglia take centre stage in neurodegenerative disease[J]. Nat Rev Immunol, 2019, 19(2): 79-80. |
18 | Pan J, Ma N, Yu B, et al. Transcriptomic profiling of microglia and astrocytes throughout aging[J]. J Neuroinflammation, 2020, 17(1): 97. |
19 | Hammond TR, Marsh SE, Stevens B. Immune signaling in neurodegeneration[J]. Immunity, 2019, 50(4): 955-974. |
20 | Martínez-Cué C, Rueda N. Cellular senescence in neurodegenerative diseases[J]. Front Cell Neurosci, 2020, 14: 16. |
21 | Thoppil H, Riabowol K. Senolytics: a translational bridge between cellular senescence and organismal aging[J]. Front Cell Dev Biol, 2019, 7: 367. |
/
〈 |
|
〉 |